iBio Changes Headquarters to Bryan, Texas

Ticker: IBIO · Form: 8-K · Filed: 2024-01-08T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, administrative-change

TL;DR

**iBio moved its HQ to Bryan, Texas, signaling a potential operational shift.**

AI Summary

iBio, Inc. filed an 8-K on January 8, 2024, primarily to update its corporate address from 600 Madison Avenue, Suite 1601, New York, NY to 8800 HSC Parkway, Bryan, Texas 77807. This change signifies a potential operational shift or consolidation for the pharmaceutical preparations company. For investors, this matters as a change in headquarters can sometimes indicate a strategic realignment, cost-cutting measures, or a move closer to key facilities or talent, which could impact future operational efficiency and financial performance.

Why It Matters

A change in headquarters can signal a strategic shift for iBio, potentially impacting operational costs, access to talent, or proximity to research facilities, all of which could influence the company's long-term value.

Risk Assessment

Risk Level: low — This filing primarily reports an administrative change of address, which typically carries minimal direct financial risk.

Analyst Insight

Investors should monitor future filings and company announcements for further details regarding the strategic implications of iBio's headquarters relocation, as it could signal broader operational changes or cost efficiencies.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What was the primary purpose of iBio, Inc.'s 8-K filing on January 8, 2024?

The primary purpose of iBio, Inc.'s 8-K filing on January 8, 2024, was to report a change in its principal executive offices and business address from New York, NY to Bryan, Texas.

What is iBio, Inc.'s new principal executive office address as reported in the filing?

iBio, Inc.'s new principal executive office address is 8800 HSC Parkway, Bryan, Texas 77807, as reported in the filing.

What was iBio, Inc.'s former business address before this change?

iBio, Inc.'s former business address was 600 Madison Avenue, Suite 1601, New York, NY 10022-1737.

On what date was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 8, 2024.

What is iBio, Inc.'s trading symbol and on which exchange is it registered?

iBio, Inc.'s trading symbol is IBIO, and it is registered on the NYSE American exchange.

Filing Stats: 633 words · 3 min read · ~2 pages · Grade level 11 · Accepted 2024-01-08 16:30:59

Key Financial Figures

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. iBio, Inc. (the "Company") has updated its corporate presentation. A copy of the updated corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and in the investor presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The investor presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical. The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures .

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. The following exhibits are furnished with this Current Report on Form 8-K: Exhibit Number Exhibit Description 99.1 iBio, Inc. Investor Presentation, dated January 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith ** Furnished herewith

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IBIO INC. Date: January 8, 2024 By: /s/ Marc A. Banjak Name: Marc A. Banjak Title: General Counsel and Corporate Secretary

View on Read The Filing